Biologic treatment for moderate to severe psoriasis launched in UK

Janssen has announced that its treatment for moderate-to-severe plaque psoriasis is now available in the UK for adult patients who are candidates for systemic therapy.

Tremfya^▼ (guselkumab) is an injectable biologic treatment for psoriasis and can be self-administered following training. Treatment requires two starter doses, one initially and the other four weeks later, followed by a maintenance dose once every eight weeks (q8w) thereafter.

“We are delighted that guselkumab is now available for patients in the UK,” said Dr Frank Wiegand, medical director, Janssen UK. “At Janssen, we are committed to bringing innovative new therapies that help to improve the lives of those living with these debilitating diseases. The availability of guselkumab in the UK provides an innovative new option to help address the continued needs of people living with plaque psoriasis.”

The marketing authorisation and subsequent launch of this therapy has been based on data from three Phase III trials — VOYAGE 1 and 2 and NAVIGATE trials.